Contrast developer Bracco Imaging has received clearance from Chinese regulators for the use of its SonoVue (sulphur hexafluoride microbubbles) ultrasound contrast agent in ultrasonography of the urinary tract.
This clinical application of SonoVue is for evaluating suspected or known vesicoureteral reflux (VUR) in neonates, infants, and children. VUR involves the retrograde flow of urine from the bladder into the ureter and toward the kidney.
SonoVue is a second-generation ultrasound contrast agent with approved clinical indications that include cardiac, vascular, liver, and breast imaging in adults, Bracco said.
